Tag Archives: abbv

4 Potential Blockbuster Drugs The FDA Just Approved

While the approval of AbbVie’s (ABBV) hepatitis C regimen Viekira Pak hogged most of the headlines, over the past week the FDA has approved a whole passel of medicines that could be blockbusters for their makers. Here’s a short list of some of the most significant: Bristol-Myers (BMY) won approval for Opdivo for melanoma on Monday, which was something of a surprise since the FDA’s deadline was in March. Opdivo is a PD-1 inhibitor, a hot new class

Express Scripts Picks AbbVie HCV Drugs Over Gilead

Pharmacy benefit manager Express Scripts (ESRX) announced Monday that it’s putting AbbVie’s newly approved hepatitis C treatment on its preferred formulary list and knocking off Gilead Sciences’ rivals. Gilead plunged 13% in morning trading in the stock market today, and AbbVie (ABBV) was down nearly 1%. Late Friday, the FDA approved Viekira Pak, a combination of three novel drugs along with an older product called ritonavir, as the second

AbbVie’s Hep C Regimen OK’d, 12-Week Cost $83,319

AbbVie’s hepatitis C regimen won FDA approval Friday, becoming the second entrant in what is already a huge market for interferon-free HCV treatments. The Viekira Pak will cost $83,319 for 12 weeks, in line with forecasts and undercutting Gilead Sciences’ (GILD) $94,500 for the same treatment length. The AbbVie (ABBV) regimen consists of three drugs: ombitasvir, paritaprevir (first developed by Enanta Pharmaceuticals (ENTA) and